Belluscura has released FY21 results that confirm the very strong operational progress detailed in the January trading update. The group's X-PLO2R portable oxygen concentrator received FDA approval in March 2021 and an equity fundraising in May has provided funding for the commercial launch. Last year, Belluscura sold 377 units, which was 150% above our initial forecasts. At the January update we raised our forecast for 2022 by +33% to 4,000 units, which we view as very conservative, particularl ....
22 Feb 2022
FY21 results update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY21 results update
Belluscura PLC (BELL:LON) | 7.5 0 (-3.2%) | Mkt Cap: 12.4m
- Published:
22 Feb 2022 -
Author:
Paul Richards -
Pages:
8
Belluscura has released FY21 results that confirm the very strong operational progress detailed in the January trading update. The group's X-PLO2R portable oxygen concentrator received FDA approval in March 2021 and an equity fundraising in May has provided funding for the commercial launch. Last year, Belluscura sold 377 units, which was 150% above our initial forecasts. At the January update we raised our forecast for 2022 by +33% to 4,000 units, which we view as very conservative, particularl ....